Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Bernstein lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $94 from $90 and maintained an Outperform rating on the shares. It noted that revenues of $875 million beat by 5%, while EPS of 46c missed by 16%, primarily due to the consensus not modeling Roctavian write-down. The firm further stated that the total revenue guidance missed by 6%, while EPS missed by 3%, with product sales guidance looking soft on Voxzogo and solid on Enzymes.

The rating update came after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q4 and full-year 2025 financial and operating results on February 23. Full year total revenues rose 13% year-over-year to $3.2 billion, led primarily by a 9% revenue growth for enzyme therapies and 26% revenue growth for VOXZOGO®. Total revenues for fiscal Q4 grew 17% year-over-year, led by 13% revenue growth for enzyme therapies and 31% revenue growth for VOXZOGO. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) also announced a definitive agreement to acquire Amicus Therapeutics, which is expected to considerably accelerate and diversify revenues.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.